Understanding liver-directed cancer treatment: how TACE works, who may benefit, and what patients should know.
Registration takes under a minute. Your joining link appears straight away, ready for your calendar.
Arpan builds the conversation from the patient's side of the table — why liver-directed treatment is so often misunderstood, and how a local procedure fits into a broader cancer strategy rather than replacing one.
Dr. Bansal performs the procedures being discussed. He walks through what TACE physically involves, how the tumour's blood supply is reached, who is assessed as suitable — and, just as importantly, who is not.
TACE is one of the most discussed liver-directed cancer treatments, yet many patients and families still have questions about what the procedure actually involves, who may benefit from it, and how it fits into a broader cancer treatment strategy.
The procedure explained step by step, in plain language — not in radiology shorthand.
The factors doctors weigh before recommending TACE — and when it isn't the right option.
TACE, TARE and ablation side by side — and why one may be chosen over another.
Submit questions in advance. The team answers as many as time allows, on the call.
Not to promote one particular treatment, but to help patients and families understand the procedure, its possibilities and limitations, and the factors doctors consider when deciding whether it is appropriate.
If you have been told TACE is an option — or told it isn't — these are the things worth understanding first.
An interventional radiologist uses imaging guidance to reach the blood vessels supplying the tumour, and delivers treatment locally. In five steps:
A small entry point is made into an artery, usually at the wrist or groin.
A very fine tube is guided through the vessels under live imaging.
The specific branch supplying the tumour is identified and selected.
Chemotherapy is released into that branch, concentrated at the tumour.
The feeding vessel is then blocked, holding the drug in place.
TACE treats a liver tumour through the artery that feeds it — delivering chemotherapy where the tumour lives, then closing off its supply line.
The liver is unusual: it has two blood supplies, and tumours and healthy tissue do not use them equally. That difference is what makes liver-directed treatment possible.
There is no single checkbox. Before TACE is recommended, a team looks at all of the following together:
Having liver metastases does not automatically mean that TACE is appropriate — or inappropriate.
The decision requires an individual assessment and a detailed imaging review.
A particularly important topic for patients with metastatic disease. Dr. Bansal covers where liver-directed treatment may be considered:
Likely one of the most valuable parts of the session for patients. What gets weighed:
"I have too many lesions, so I cannot have liver-directed treatment."
The answer is more nuanced than that — and the session explains why.
Four different tools, four different jobs. A simple comparison of what each one actually does:
| Treatment | Basic approach |
|---|---|
| TACE | Local chemotherapy delivered through the artery, followed by embolization of the tumour's feeding vessel. |
| TARE | Radioactive microspheres delivered through the arterial blood supply. |
| Ablation | Direct destruction of selected tumour tissue. |
| Systemic therapy | Treatment delivered throughout the body rather than to one site. |
Which one is preferred depends on:
There is no single "best" liver-directed treatment for every patient.
Much of the anxiety around TACE comes from not knowing what the day looks like. This part of the session is deliberately practical.
What happens before the procedure and how you are prepared for it.
How the patient is positioned and how vascular access is obtained.
How the catheter is guided and how the tumour is identified on imaging.
How the chemotherapy and embolization are delivered to the target vessel.
What sedation or anaesthesia is typically used, and what you are likely to feel.
How you are monitored afterwards and what the stay usually involves.
What the first days typically look like as the body responds.
What is common, what is expected, and what should be reported.
What is checked, and why liver function is watched closely.
When imaging is repeated and how response is assessed.
When another treatment — including a repeat TACE — may be considered.
Treatment doesn't end when the procedure finishes. Follow-up is an important part of liver-directed therapy.
A balanced session has to cover what can go wrong and what TACE cannot do. Dr. Bansal will address:
TACE is not appropriate for every patient. Understanding when it is not the right choice is as valuable as understanding when it is.
Local treatment and systemic treatment do not necessarily have to compete with each other. For some patients, the strategy involves both at once:
Treating visible disease locally + controlling microscopic and systemic disease
Depending on the individual case, the broader strategy may draw on any of these — the question is which combination makes sense for that particular patient.
Only then does the team decide between:
Starting from the patient's perspective: why TACE confuses people, and why no single treatment suits everyone. Key message — TACE is one tool within a much larger treatment landscape.
Transarterial chemoembolization in simple language: access, catheter, tumour-feeding artery, local chemotherapy, embolization.
How liver tumours get their blood, why the arterial route is an opportunity, and what embolization is meant to achieve.
Cancer type, lesion number, size and location, lobe involvement, liver function, vascular anatomy, prior treatment and overall health.
Primary liver tumours, colorectal and breast metastases, and the difference between dominant lesions and diffuse disease.
Small, large, multiple and diffuse disease — and why distribution matters more than a headline count.
A plain comparison, and why one may be preferred over another for a given patient.
Preparation, positioning, access, catheter guidance, sedation, monitoring, hospital stay and recovery.
Recovery, possible symptoms, blood tests, follow-up imaging, and how response is assessed.
An honest look at complications, liver stress, untreatable lesions, and when TACE is simply not appropriate.
Local and systemic treatment working together rather than competing — and what a combined strategy can look like.
The full decision framework, from history and imaging through to treatment objectives.
Your submitted questions, answered on the call by both speakers.
Bring yours — or submit them in advance after registering. Here's the kind of thing patients send in:
I've been told my liver lesions are too small for TACE. Is that always the case?
Can TACE be used for metastatic colorectal cancer?
Can TACE treat multiple lesions?
Can both lobes of the liver be treated?
How is TACE different from TARE?
Can TACE be combined with chemotherapy?
How do you know whether TACE has worked?
How long does recovery usually take?
Can TACE be repeated?
What should I ask my interventional radiologist before deciding?
Fill a short form — name, email, phone, and where you're joining from. It takes under a minute.
Your Zoom link appears the moment you register, with one-tap buttons to save it to your calendar.
Add the questions you'd like answered. Both speakers review them before the session.
Nothing. The webinar is free to attend. You only need to register so we can send you the Zoom link and calendar invite.
No. The whole point of the session is to explain TACE in plain language. Where a technical term is unavoidable, it gets explained before it's used.
No. Suitability for TACE depends on your clinical history, your liver function and a detailed review of your imaging — none of which can be assessed in a group webinar. What the session does is help you understand the procedure and the questions worth asking your own medical team.
No. A significant part of the discussion covers liver metastases from other cancers, including colorectal and breast cancer, and when liver-directed treatment may or may not be considered.
Yes. After registering you can submit the questions you'd like answered. Both speakers review them beforehand and answer as many as time allows during the live Q&A.
Immediately. Your link is shown on the confirmation page the moment you register, with one-tap buttons to save it to Google Calendar, Apple Calendar or Outlook. Zoom also emails it to you, and sends a reminder before the session.
Register anyway. If you're on the list, we'll email you a recording after the session where available.
Ninety minutes with Arpan Talwar and Dr. Abhishek Bansal on what TACE is, who it may help, and the questions worth asking before you decide anything.
Register free now
